Regional and racial variations in the utilization of endoscopic retrograde cholangiopancreatography among pancreatic cancer patients in the United States.

ABSTRACT:

Background

Pancreatic cancer is projected to become the second leading cause of cancer-related deaths by 2030. Endoscopic retrograde cholangiopancreatography (ERCP) is recommended as first-line therapy for biliary decompression in pancreatic cancer. The aim of our study was to characterize geographic and racial/ethnic disparities in ERCP utilization among patients with pancreatic cancer.

Methods

Retrospective cohort study using the US Surveillance, Epidemiology, and End Results (SEER)-Medicare database to identify patients diagnosed with pancreatic cancer from 2003-2013. The primary outcome was receipt of ERCP, with or without stent placement, vs any non-ERCP biliary intervention.

Results

Of the 36 619 patients with pancreatic cancer, 37.5% (n = 13 719) underwent an E

SUBMITTER: Tavakkoli A 

PROVIDER: S-EPMC6601581 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature